We are dedicated to developing tomorrow’s drugs against oxidative stress, helping millions of people to a better life by preventing and treating serious kidney diseases. ROSgard, our biological drug candidate, mimics the body’s own powerful defense system against oxidative stress. Designed with a natural “homing” to the kidneys, ROSgard prevents kidney damage by protecting, cleaning and repairing the exposed cells and tissues.

Our early clinical program consists of two phase I studies on healthy subjects and one phase Ib study on patients undergoing open-heart surgery.

Read more


ROSgard, our drug candidate, is designed to mimic the body's own defense system against oxidative stress by protecting, cleaning and repairing exposed cells and tissue.

Read more


Acute kidney injury is a large market. The estimated annual value is USD 6.3 bn in the USA and GBP 500 mn in the UK.

Read more


Press releases
  • 17 Mar 2020

    Guard Therapeutics announces positive top line results from a clinical phase 1a study of ROSgard

    Read more
Show more
Calendar & reports
News, reports & presentations